Tharimmune Inc. (THAR)
NASDAQ: THAR
· Real-Time Price · USD
1.82
-0.12 (-6.20%)
At close: Jul 01, 2025, 10:26 AM
-6.20% (1D)
| Bid | 1.78 |
| Market Cap | 4.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.48M |
| EPS (ttm) | -7.85 |
| PE Ratio (ttm) | -0.23 |
| Forward PE | -2.4 |
| Analyst | Buy |
| Ask | 1.87 |
| Volume | 15,687 |
| Avg. Volume (20D) | 97,459 |
| Open | 1.96 |
| Previous Close | 1.94 |
| Day's Range | 1.80 - 1.96 |
| 52-Week Range | 0.95 - 6.39 |
| Beta | 1.06 |
About THAR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol THAR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for THAR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 months ago
+10.84%
Tharimmune shares are trading higher after it anno...
Unlock content with
Pro Subscription
8 months ago
+68.97%
Tharimmune shares are trading higher after the company announced it received EMA feedback on its TH104 clinical program. The design and main features of the proposed Phase 2 study were deemed acceptable and general guidance was also provided for a future Phase 3 study.
2 months ago · accessnewswire.com
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL ConferencesBRIDGEWATER, NJ / ACCESS Newswire / May 1, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeuti...
2 months ago · accessnewswire.com
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of DirectorsBRIDGEWATER, NJ / ACCESS Newswire / April 30, 2025 / Tharimmune, Inc., (NASDAQ:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therape...
